About Prosit Sole

Unmet Medical Needs, Our Social Responsibility

At Prosit Sole, we focus on developing innovative protein therapeutics that address the unmet medical needs for life-threatening rare diseases. Prosit Sole established an advanced Prositsole Protein Optimize Platform (P-POP), a Biologics discovery technology, patented in the US and China, that enables us to discover first-in-class or best-in-class biologics, with excellent efficacy and favorable safety profile. Currently, Prosit Sole has 4 Biologics in various stages of development, the lead product candidates are PEGINF-lchimeric (currently being pursued for IND in the US) and a FGF-18 chimeric (currently in pre-clinical development). 

For some severe diseases, there is no approved treatment options so far, the life-threatening nature of such acute or chronic sickness may take people’s life and destroy happiness of a family. While, some illness is no so serious but it makes patients suffering in de-quality life. Prosit Sole, with a team of senior bio-pharmaceutical scientists, we are to transfer whole life’s science to medicine target on making up unfulfilled medical needs. A new treatment will realize a scientist’s value, as well as fulfil an enterprise’s social responsibility.

Prosit Sole, a biotechnology company focusing on protein therapeutics, was founded by Dr. Hongyu Liu in 2013 in Beijing, China. and The company built its R&D Center and manufacturing facility in GuAn Peptite Valley, Hebei, China, which is in the close vicinity of Beijing (1.5 hour driving from the city center). The GuAn Facility is led by Dr. Zhihua Zou, Dr. Dan Yuan, and Dr. Mingzhi Zhao. Prosit Sole also established a Clinical Research Center led by Dr. Don Foster and located in Seattle, WA..

How can we develop First-in-class or Best-in-class therapeutics

Prosit Sole established an advanced Prositsole Protein Optimize Platform (P-POP), a biologics discovery technology, patented in the US and China, that enables us to discover first-in-class or best-in-class biologics, with excellent efficacy and favorable safety profile. Currently, Prosit Sole has 4 biologics in various stages of development, the lead product candidates are PEGINF-γ chimeric (currently being pursued for IND in the US) , and a FGF-18 chimeric, (currently in pre-clinical development).